NASH

How many potential benefits does the cannabis plant with its 550+ chemical compounds hold for our health? No one knows, but as scientists have increased opportunities to research it, each new study provides another piece of this large puzzle. This time, researchers at the...

Lipocine Inc (NASDAQ: LPCN) has announced topline 36-week results from its Phase 2 proof of concept LiFT study investigating LPCN 1144 in Non-Alcoholic Steatohepatitis (NASH). LPCN 1144 comprises an orally delivered prodrug of endogenous testosterone (T). At 12 weeks...

CohBar Inc (NASDAQ: CWBR) announced topline results from the Phase 1a/1b study of CB4211 for nonalcoholic steatohepatitis (NASH) and obesity.  The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events.  After...

The FDA has agreed with Galmed Pharmaceuticals Ltd's (NASDAQ: GLMD) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR study without the need for additional studies other than planned limited pharmacology studies relating to Aramchol...

Theratechnologies Inc (NASDAQ: THTX) has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for its Phase 3 trial for tesamorelin in nonalcoholic steatohepatitis (NASH). The trial will include a futility analysis after...

CohBar Inc (NASDAQ: CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity.  The process of data entry and final validation, which must be concluded before database lock, is...

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive topline results from its Phase 2a AMBITION NASH clinical trial evaluating CRV431, a potent inhibitor of cyclophilins. In the trial, CRV431 blood concentrations after oral dosing of either 75 mg or 225 mg once daily...

Akero Therapeutics Inc (NASDAQ: AKRO) has announced full results of the main portion of its Phase 2a BALANCED trial of efruxifermin (EFX) in NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The manuscript provides a comprehensive analysis showing that pre-...

Akero Therapeutics Inc (NASDAQ: AKRO) has announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH) patients with F1-F3 fibrosis. Data were presented at the 2021 International Liver Congress.  These analyses...

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non-alcoholic steatohepatitis (NASH). TERN-101 was generally well-tolerated in the...

Today, NGM Biopharmaceuticals Inc (NASDAQ: NGM) reported disappointing results from the Phase 3 trial of aldafermin in NASH patients. What Happened: The primary endpoint of an improvement in fibrosis with no worsening of NASH among the 107 patients taking a 0.3 mg, 1 mg, or 3 mg...

Germany-based Boehringer Ingelheim has accepted Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) GalXC RNAi candidate for advancement under the existing agreement between the companies to discover and develop novel therapies for the treatment of chronic liver diseases. Dubbed DCR-...

NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3). The study did not meet its primary endpoint evaluating a dose-...

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date despite the broader market turbulence. NGM's NASH Data Due:  NGM has scheduled conference calls on Monday at...

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced interim data from the Phase 2 trial evaluating its selective cortisol modulator miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). The company had to suspend the trial after most patients...